Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
This grant supports planning of cancer prevention and control clinical trials to enhance trial design, feasibility, and reduce costs for effective cancer interventions.
Funder: National Institutes of Health
Due Dates: June 25, 2025 | October 25, 2025 | February 25, 2026 | June 25, 2026 | October 25, 2026 | February 25, 2027 | June 25, 2027 | October 25, 2027
Funding Amounts: Up to $225,000/year; max $450,000 direct costs over 3 years (no pilot trial) or $600,000 over 3 years (with pilot/feasibility trial); 3-year project period
Summary: Supports planning activities and feasibility studies to optimize the design and implementation of future cancer prevention and control clinical trials.
Key Information: Preliminary efficacy/effectiveness data for the intervention are required; non-domestic (foreign) organizations are eligible.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, funds planning activities and preparatory studies to address critical gaps in the design and implementation of future multi-center Phase II or later phase clinical trials in cancer prevention and control. The grant is intended to help investigators collect feasibility data, refine study protocols, test recruitment and retention strategies, and address operational or statistical challenges before launching a full-scale trial. The ultimate goal is to improve the rigor, feasibility, and cost-effectiveness of future cancer clinical trials.
